Clinical data | |
---|---|
Trade names | Nexavar, others |
Other names | Sorafenib tosylate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607051 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 38–49% |
Protein binding | 99.5% |
Metabolism | Liver oxidation and glucuronidation (CYP3A4 & UGT1A9-mediated) |
Elimination half-life | 25–48 hours |
Excretion | Feces (77%) and urine (19%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.110.083 |
Chemical and physical data | |
Formula | C21H16ClF3N4O3 |
Molar mass | 464.83 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Sorafenib, sold under the brand name Nexavar,[3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Nexavar FDA label
was invoked but never defined (see the help page).